Skip to main content
SpringerLink
Log in

Erstlinientherapie beim metastasierten Mammakarzinom

Gibt es einen Favoriten bei den Tubulininhibitoren?

  • journal club
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Mross K. InFo Onkologie. 2008;11(4):260–1.

    Google Scholar 

  2. Mross K (Hrsg.). Angiogeneseinhibition in der Onkologie. 1. Auflage. Bremen: UniMed Verlag; 2007.

Originalie

  • Rugo HS et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel or ixabepilone with bevacizumab as first line therapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H. J Clin Oncol. 2015;33(21):2361–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Freiburg, Deutschland

    Klaus Mross

Authors
  1. Klaus Mross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Mross.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mross, K. Gibt es einen Favoriten bei den Tubulininhibitoren?. Info Onkol. 18, 32–34 (2015). https://doi.org/10.1007/s15004-015-5168-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-015-5168-9

Schlüsselwörter

Search

Navigation